Title: Concurrent Nonalcoholic Fatty Liver Disease May Decrease Liver Fibrosis Severity in
Patients with Primary Biliary Cholangitis
Version: 1 Date: 11 Apr 2025
Reviewer's report:
I have read the manuscript "Concurrent Nonalcoholic Fatty Liver Disease Decreased Liver
Fibrosis Severity in Patients with Primary Biliary Cholangitis " with great interest, but some
issues require clarification.
1. The authors should explain what interactions and mechanisms ameliorated fibrosis when
NAFLD and PBC coexist.
2. The authors have data for APRI and FIB 4 scores after 1 year of UDCA administration, but
please add those data at baseline.
3. The authors noted that at baseline, significantly more patients with PBC and NAFLD were
cirrhotic than those with only PBC. If there were no significant difference between the two
groups in APRI or FIB4 at baseline, that consideration would be necessary.
4. I suggest adding platelet counts to the Table, as well as biochemical values (ALT, ALT, GGT,
etc.) and platelet counts after one year.
5. Since ALP and Albuin included in the Globe score formula were significantly different at
baseline in the Globe score analysis, it is necessary to examine the Globe score by propensity
score matching adjusted for ALP and ALB at baseline as subanalysis.
Title: Concurrent Nonalcoholic Fatty Liver Disease May Decrease Liver Fibrosis Severity in
Patients with Primary Biliary Cholangitis
Version: 1 Date: 11 Apr 2025
Reviewer's report:
I have read the manuscript "Concurrent Nonalcoholic Fatty Liver Disease Decreased Liver
Fibrosis Severity in Patients with Primary Biliary Cholangitis " with great interest, but some
issues require clarification.
1. The authors should explain what interactions and mechanisms ameliorated fibrosis when
NAFLD and PBC coexist.
2. The authors have data for APRI and FIB 4 scores after 1 year of UDCA administration, but
please add those data at baseline.
3. The authors noted that at baseline, significantly more patients with PBC and NAFLD were
cirrhotic than those with only PBC. If there were no significant difference between the two
groups in APRI or FIB4 at baseline, that consideration would be necessary.
4. I suggest adding platelet counts to the Table, as well as biochemical values (ALT, ALT, GGT,
etc.) and platelet counts after one year.
5. Since ALP and Albuin included in the Globe score formula were significantly different at
baseline in the Globe score analysis, it is necessary to examine the Globe score by propensity
score matching adjusted for ALP and ALB at baseline as subanalysis.
Please review this paper.
user
Title: Concurrent Nonalcoholic Fatty Liver Disease May Decrease Liver Fibrosis Severity in
Patients with Primary Biliary Cholangitis
Version: 1 Date: 11 Apr 2025
Reviewer's report:
I have read the manuscript "Concurrent Nonalcoholic Fatty Liver Disease Decreased Liver
Fibrosis Severity in Patients with Primary Biliary Cholangitis " with great interest, but some
issues require clarification.
1. The authors should explain what interactions and mechanisms ameliorated fibrosis when
NAFLD and PBC coexist.
2. The authors have data for APRI and FIB 4 scores after 1 year of UDCA administration, but
please add those data at baseline.
3. The authors noted that at baseline, significantly more patients with PBC and NAFLD were
cirrhotic than those with only PBC. If there were no significant difference between the two
groups in APRI or FIB4 at baseline, that consideration would be necessary.
4. I suggest adding platelet counts to the Table, as well as biochemical values (ALT, ALT, GGT,
etc.) and platelet counts after one year.
5. Since ALP and Albuin included in the Globe score formula were significantly different at
baseline in the Globe score analysis, it is necessary to examine the Globe score by propensity
score matching adjusted for ALP and ALB at baseline as subanalysis.
assistant